8-K: Gyre Therapeutics Announces Third Quarter 2024 Financial Results and Business Update, Anticipates Key Milestones in 2025

Gyre Therapeutics reported its third quarter 2024 financial results, highlighted by $25.5 million in revenue and progress in clinical trials, with several key milestones expected in 2025.

Summary

• Gyre Therapeutics announced its financial results for the third quarter and nine months ended September 30, 2024, along with a business update.
• The company reported revenue of $25.5 million for the third quarter of 2024, compared to $32.0 million for the same period in 2023, a decrease of $6.5 million primarily due to lower anti-fibrosis drug sales.
• For the nine months ended September 30, 2024, revenue was $77.9 million, down from $86.3 million in the same period of 2023, with an $8.4 million decrease mainly from anti-fibrosis drug sales.
• Net income for the third quarter was $2.9 million, compared to $7.5 million in the same period of 2023.
• Net income for the nine months ended September 30, 2024, was $17.3 million, compared to $15.5 million for the same period in 2023.
• As of September 30, 2024, Gyre had cash and cash equivalents of $15.9 million, which is expected to fund operations for at least 12 months.
• The company anticipates the commercial launch of avatrombopag maleate tablets and nintedanib in the PRC in 2025.
• The pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis in the PRC has completed, with topline data expected in the first quarter of 2025.
• Gyre plans to initiate a Phase 2 trial of F351 in MASH-associated liver fibrosis in the U.S. in 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and upcoming product launches, but tempered by the decrease in revenue and net income compared to the previous year. The company's cash position is a positive factor, but the economic risks and competition are also significant.

Positives

• Gyre has completed its pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis, with results expected in early 2025.
• The company is on track to launch two new products, avatrombopag and nintedanib, in the PRC in 2025.
• Gyre has a strong cash position of $15.9 million, expected to fund operations for at least 12 months.
• The company is expanding its clinical development program with a planned Phase 2 trial of F351 in MASH-associated liver fibrosis in the U.S.
• Gyre Pharmaceuticals generated $25.3 million in sales of ETUARY in the third quarter of 2024.
• Net income for the nine months ended September 30, 2024, was $17.3 million, an increase compared to $15.5 million for the same period in 2023.

Negatives

• Revenues for the third quarter of 2024 decreased by $6.5 million compared to the same period in 2023, primarily due to lower anti-fibrosis drug sales.
• Revenues for the nine months ended September 30, 2024, decreased by $8.4 million compared to the same period in 2023, primarily due to lower anti-fibrosis drug sales.
• Net income for the third quarter of 2024 decreased to $2.9 million, compared to $7.5 million in the same period of 2023.
• General and administrative expenses increased significantly due to costs associated with being a public company.

Risks

• The company's revenue is susceptible to fluctuations in the Chinese economy, which has significantly affected demand for anti-fibrosis drugs.
• The success of the planned product launches and clinical trials is subject to regulatory approvals and market acceptance.
• The company's ability to raise additional capital is a risk factor.
• There is competition from other companies in the pharmaceutical market.
• The timing of clinical trial readouts and regulatory approvals is uncertain.

Future Outlook

Gyre anticipates several key milestones in 2025, including the commercial launch of avatrombopag and nintedanib in the PRC, and the initiation of a Phase 2 trial of F351 in MASH-associated liver fibrosis in the U.S. The company expects its cash resources to fund operations for at least 12 months following the issuance of the condensed financial statements.

Management Comments

• Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics, stated that the team has made great progress and recently achieved a significant milestone with the final patient completing the Phase 3 trial for F351 in CHB-associated liver fibrosis.
• Han Ying also expressed confidence in Gyre's ability to deliver in the clinic and the commercial market for patients in need, citing upcoming milestones in 2025.

Industry Context

This announcement reflects the ongoing efforts in the biotechnology industry to develop treatments for chronic organ diseases, particularly liver fibrosis. Gyre's focus on both clinical development and commercialization in China and the U.S. positions it to address significant unmet medical needs. The company's expansion into new therapeutic areas like MASH and PAH aligns with broader industry trends.

Comparison to Industry Standards

• Gyre's revenue decline in anti-fibrosis drug sales reflects a broader trend of market fluctuations and economic impacts on healthcare spending in China, which has also impacted other pharmaceutical companies operating in the region.
• The company's focus on developing treatments for liver fibrosis and pulmonary diseases aligns with the industry's emphasis on addressing chronic conditions with high unmet needs, similar to companies like Gilead Sciences and Intercept Pharmaceuticals in the liver disease space.
• The planned commercial launches of avatrombopag and nintedanib in China are comparable to other companies' strategies of leveraging existing sales platforms to introduce new products in established markets, such as Novartis and Roche.
• Gyre's clinical development program for F351 in MASH-associated liver fibrosis is similar to other companies' efforts to develop treatments for this growing disease area, such as Madrigal Pharmaceuticals and Viking Therapeutics.
• The company's cash position of $15.9 million is relatively modest compared to larger pharmaceutical companies, but it is sufficient to fund operations for at least 12 months, which is a common benchmark for biotech companies in their development phase.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net income, but encouraged by the progress in clinical trials and upcoming product launches.
• Employees may be affected by changes in staffing levels in the research and development department.
• Patients in the PRC may benefit from the upcoming commercial launches of avatrombopag and nintedanib.
• Customers may be impacted by the fluctuations in the Chinese economy affecting demand for anti-fibrosis drugs.
• Suppliers may be affected by changes in production and sales volumes.
• Creditors may be interested in the company's cash position and ability to fund operations.

Next Steps

• Gyre will report topline data from the Phase 3 trial of F351 in CHB-associated liver fibrosis in the first quarter of 2025.
• The company plans to commercially launch avatrombopag maleate tablets in the PRC in the first half of 2025.
• Gyre intends to commercialize nintedanib in the PRC in 2025.
• The company plans to initiate a Phase 2 clinical trial of F351 in MASH-associated liver fibrosis in the U.S. in 2025.
• Gyre expects to initiate a Phase 1 trial of F230 for the treatment of PAH in 2025.

Key Dates

Keywords

Gyre Therapeutics, F351, liver fibrosis, MASH, CHB, avatrombopag, nintedanib, ETUARY, clinical trials, biotechnology, pharmaceuticals, China, commercial launch, financial results